Born: 1973.
Title: Member and Chairman of the Board since 2026.
Education: Master's degree in economics and Bachelor's degree in business administration from Lund University.
Background: Over 25 years of experience in healthcare investments. Previously a majority owner of the fund management company HealthInvest Partners AB. Earlier roles include analyst and portfolio manager specializing in the healthcare sector at Carnegie Investment Bank AB. Founder and owner of Hallberg Management AB.
Other directorships: Hallberg Management AB.
Shares in Medivir: 94,000,000 ordinary shares.
Born: 1973.
Title: Member of the Board since 2024.
Education: Ph.D. in Clinical Immunology from Uppsala University.
Background: More than 25 year’s academic drug development experience within immune oncology and is adjunct Professor of immunotherapy at Uppsala University. She is the CEO of Lokon Pharma since 2012 and a scientific advisor at venture cap Nexttobe. Further, she has >10 year’s board experience from privately owned biotech’s such as Chemilia, Bioimics and the public company Hansa Biopharma.
Other directorships: Chairperson of the Board of Repos Pharma. Member of the Board of Lokon Pharma.
Shares in Medivir: 6,309 ordinary shares.
Born: 1963.
Title: Member of the Board since 2024.
Education: PhD from Karolinska Institutet/MEB with a focus on statistics, MScs in pharmacy and mathematical statistics.
Background: Broad experience from drug development, especially regulatory affairs, from Regulatory Authorities, pharmaceutical companies and consultancy. Founder of the consulting company SDS Life Science which offers expert services within drug development and statistics. Great interest in the design of clinical studies and communication with authorities.
Other directorships: Member of the Boards of MedCap AB, Akiram Therapeutics, Attgeno AB and Lett Renovering AB.
Shares in Medivir: 0.
Born: 1975.
Education: Ph.D. in Cellular and Molecular Biology and MBA.
Background: Founder of Alder Therapeutics as well as founder and member of the Board of BioLamina.Over 25 years of experience in commercializing scientific ideas with a focus on business development, project management, marketing and sales. Solid experience in clinical, regulatory and commercial aspects of drug development.
Other directorships: Member of the Board of BioLamina AB
Shares in Medivir: 0.